Medtronic PLC
NYSE:MDT
Intrinsic Value
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. [ Read More ]
The intrinsic value of one MDT stock under the Base Case scenario is 93.22 USD. Compared to the current market price of 79.48 USD, Medtronic PLC is Undervalued by 15%.
Valuation Backtest
Medtronic PLC
Run backtest to discover the historical profit from buying and selling MDT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Medtronic PLC
Current Assets | 22.5B |
Cash & Short-Term Investments | 8.3B |
Receivables | 6B |
Other Current Assets | 8.2B |
Non-Current Assets | 68.3B |
Long-Term Investments | 1.6B |
PP&E | 5.8B |
Intangibles | 54.9B |
Other Non-Current Assets | 6B |
Current Liabilities | 9.8B |
Accounts Payable | 2B |
Accrued Liabilities | 5.3B |
Short-Term Debt | 1B |
Other Current Liabilities | 1.5B |
Non-Current Liabilities | 29.3B |
Long-Term Debt | 24.2B |
Other Non-Current Liabilities | 5.1B |
Earnings Waterfall
Medtronic PLC
Revenue
|
32.3B
USD
|
Cost of Revenue
|
-11.1B
USD
|
Gross Profit
|
21.2B
USD
|
Operating Expenses
|
-14.8B
USD
|
Operating Income
|
6.4B
USD
|
Other Expenses
|
-2.2B
USD
|
Net Income
|
4.2B
USD
|
Free Cash Flow Analysis
Medtronic PLC
What is Free Cash Flow?
MDT Profitability Score
Profitability Due Diligence
Medtronic PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Medtronic PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
MDT Solvency Score
Solvency Due Diligence
Medtronic PLC's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Medtronic PLC's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDT Price Targets Summary
Medtronic PLC
According to Wall Street analysts, the average 1-year price target for MDT is 95.99 USD with a low forecast of 75.75 USD and a high forecast of 109.2 USD.
Ownership
MDT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MDT Price
Medtronic PLC
Average Annual Return | 2.84% |
Standard Deviation of Annual Returns | 26.21% |
Max Drawdown | -46% |
Market Capitalization | 105.7B USD |
Shares Outstanding | 1 327 820 032 |
Percentage of Shares Shorted | 0.94% |
MDT News
Last Important Events
Medtronic PLC
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Medtronic PLC
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. The company is headquartered in Dublin, Dublin and currently employs 90,000 full-time employees. The firm develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients. The firm has four operating and reportable segments that primarily develop, manufacture, distribute, and sell device-based medical therapies and services: the Cardiovascular Portfolio, the Medical Surgical Portfolio, the Neuroscience Portfolio, and the Diabetes Operating Unit. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions.
Contact
IPO
Employees
Officers
The intrinsic value of one MDT stock under the Base Case scenario is 93.22 USD.
Compared to the current market price of 79.48 USD, Medtronic PLC is Undervalued by 15%.